Edition:
United Kingdom

Edap Tms SA (EDAP.OQ)

EDAP.OQ on NASDAQ Stock Exchange Global Market

2.50USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$2.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,848
52-wk High
$3.84
52-wk Low
$2.25

Chart for

About

EDAP TMS S.A. (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of... (more)

Overall

Beta: 1.03
Market Cap(Mil.): $93.56
Shares Outstanding(Mil.): 29.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 148.59 16.60
EPS (TTM): -- -- --
ROI: -- 9.38 10.66
ROE: -- 14.72 14.30

BRIEF-EDAP Reports First HIFU Treatments Performed At Acibadem Hospital, Istanbul

* EDAP'S FOCAL ONE® ROBOTIC HIFU TREATMENTS PERFORMED AT ACIBADEM HOSPITAL, ISTANBUL, TURKEY Source text for Eikon: Further company coverage:

18 Dec 2017

BRIEF-EDAP signs exclusive agreement with Theraclion to distribute Echopulse® in France

* EDAP signs exclusive agreement with Theraclion to distribute Echopulse® HIFU product in France

09 Oct 2017

BRIEF-Theraclion announces exclusive distribution agreement with EDAP TMS France

* THERACLION ANNOUNCES EXCLUSIVE DISTRIBUTION AGREEMENT WITH EDAP TMS FRANCE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

09 Oct 2017

BRIEF-Edap announces FDA clearance of its Ablatherm-Fusion device

* Edap announces FDA clearance of its Ablatherm-Fusion® device

04 Oct 2017

BRIEF-Edap Tms SA submits new 510(k) application for its Focal One device

* Edap Tms SA - company submitted a new 510(k) application for its focal one device, including an updated clinical section for FDA review Source text for Eikon: Further company coverage:

11 Sep 2017

Competitors

Earnings vs. Estimates